Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
Intercept Pharmaceuticals (Nasdaq: ICPT) announced that CEO Jerry Durso will present at the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq: ICPT) announced that CEO Jerry Durso will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 12:00 p.m. PT. The presentation will focus on the company's innovative therapeutics for non-viral liver diseases. A live audio webcast of the event will be available and later archived on Intercept's investor webpage for four weeks. Intercept specializes in developing treatments for conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was +5.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, will give a corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference. Intercept’s presentation is scheduled for Thursday, January 12, at 12:00 p.m. Pacific Time.
A live audio webcast of the event can be found here. The webcast will also be available on the investor page of Intercept’s website as an audio archive for approximately four weeks following the presentation.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.